depression on semaglutide GLP-1 drugs tied to lower brain inflammation, higher risk Semaglutide Attenuates Anxious and Depressive-Like

Additionally, efficacy concerns might lead to batch recalls, regulatory issues or expensive reimbursement claims

It runs through December 31, 2027, and requires meeting BMI-based clinical criteria

One method, known as molecular hiving, tags the first amino acid with long soluble hydrophobic anchor molecules, which can later be removed

Many have advocated that the associations between low mood, suicidal behavior and anti-obesity drugs such as GLP-1RAs are confounded by the pre-existing higher prevalence of neuropsychiatric disorders observed in people living with obesity compared with the general population 236

Swipe through for the vote breakdown, what's actually being evaluated, and where we really are in the regulatory timeline